NCT00004866View on ClinicalTrials.gov

DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2000

Primary Completion Date

September 30, 2003

Study Completion Date

September 30, 2003

Conditions
Cervical Cancer
Interventions
DRUG

exatecan mesylate

Trial Locations (6)

10019

St. Luke's-Roosevelt Hospital, New York

10461

Albert Einstein Clinical Cancer Center, The Bronx

37203

Brookview Research, Inc., Nashville

43614

Ruppert Health Center, Toledo

75246

Texas Oncology PA (TOPA) at Baylor-Sammons, Dallas

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT00004866 - DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix | Biotech Hunter | Biotech Hunter